Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of fixed-dose durvalumab with or without tremelimumab in advanced solid malignancies
NL-OMON48778Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of durvalumab and tremelimumab in Non-hematologic malignancy, transitional cell carcinoma (TCC), non-urothelial carcinoma of the urinary tract and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence and characterization of adverse events of special interest and Module A adverse events of special interest. Started Jan 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
Non-hematologic malignancytransitional cell carcinoma (TCC)non-urothelial carcinoma of the urinary tractbladder cancer
Beyond the preview
Go deeper on NL-OMON48778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48778.